{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:11:25Z","timestamp":1791983485722,"version":"4.4.0"},"reference-count":64,"publisher":"Impact Journals, LLC","issue":"29","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,7,19]]},"DOI":"10.18632\/oncotarget.9638","type":"journal-article","created":{"date-parts":[[2016,5,26]],"date-time":"2016-05-26T21:30:26Z","timestamp":1464298226000},"page":"45317-45330","source":"Crossref","is-referenced-by-count":17,"title":["Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with <i>BRCA1<\/i> mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited <i>BRCA1<\/i> mutations"],"prefix":"10.18632","volume":"7","author":[{"given":"Laudine","family":"Communal","sequence":"first","affiliation":[{"name":"UMRS 1007, Saints P\u00e8res, Paris Descartes University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Vilasco","sequence":"additional","affiliation":[{"name":"UMRS 1007, Saints P\u00e8res, Paris Descartes University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Hugon-Rodin","sequence":"additional","affiliation":[{"name":"UMRS 1007, Saints P\u00e8res, Paris Descartes University, Paris, France"},{"name":"UF de Gyn\u00e9cologie-Endocrinienne, Paris Descartes University, AP-HP, H\u00f4pital Cochin, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Courtin","sequence":"additional","affiliation":[{"name":"UMRS 1007, Saints P\u00e8res, Paris Descartes University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najat","family":"Mourra","sequence":"additional","affiliation":[{"name":"Service d'Anatomie et Cytologie Pathologiques, AP-HP, H\u00f4pital Saint-Antoine, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najiba","family":"Lahlou","sequence":"additional","affiliation":[{"name":"Service de Biologie Hormonale, Paris Descartes University, AP-HP, H\u00f4pital Cochin, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morwenna","family":"Le Guillou","sequence":"additional","affiliation":[{"name":"CNRS UMR8200 Gustave Roussy, Stabilit\u00e9 g\u00e9n\u00e9tique et Oncog\u00e9n\u00e8se, Paris-Saclay University, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel Perrault","family":"de Jotemps","sequence":"additional","affiliation":[{"name":"Service de Chirurgie Plastique et Reconstructrice, Clinique Hartmann, Neuilly sur Seine, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Pierre","family":"Chauvet","sequence":"additional","affiliation":[{"name":"D\u00e9partement de S\u00e9nologie, Centre Oscar Lambret, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Chaouat","sequence":"additional","affiliation":[{"name":"Service de Chirurgie Plastique Reconstructrice et Esth\u00e9tique et Chirurgie des Br\u00fbl\u00e9s, Denis Diderot University, AP-HP, H\u00f4pital Saint-Louis, Paris"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Pujol","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire, Montpellier University, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Feunteun","sequence":"additional","affiliation":[{"name":"CNRS UMR8200 Gustave Roussy, Stabilit\u00e9 g\u00e9n\u00e9tique et Oncog\u00e9n\u00e8se, Paris-Saclay University, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzette","family":"Delaloge","sequence":"additional","affiliation":[{"name":"Breast Cancer Group, Gustave Roussy Cancer Campus, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Forgez","sequence":"additional","affiliation":[{"name":"UMRS 1007, Saints P\u00e8res, Paris Descartes University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Gompel","sequence":"additional","affiliation":[{"name":"UMRS 1007, Saints P\u00e8res, Paris Descartes University, Paris, France"},{"name":"UF de Gyn\u00e9cologie-Endocrinienne, Paris Descartes University, AP-HP, H\u00f4pital Cochin, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,5,26]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1158\/2159-8290.CD-12-0221","article-title":"Mechanisms of BRCA1 tumor suppression","volume":"2","author":"Livingston","year":"2012","journal-title":"Cancer discovery"},{"key":"2","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1042\/BST0340633","article-title":"Cellular functions of the BRCA tumour-suppressor proteins","volume":"34","author":"Boulton","year":"2006","journal-title":"Biochemical Society transactions"},{"key":"3","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/jnci\/djt095","article-title":"Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE","volume":"105","author":"Cole","year":"2013","journal-title":"Journal of the National Cancer Institute"},{"key":"4","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2","volume":"302","author":"Mandell","year":"2003","journal-title":"Science"},{"key":"5","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1158\/1055-9965.EPI-14-0884","article-title":"Breast cancer risk associated with oestrogen exposure and truncating mutation location in BRCA1\/2 carriers","volume":"24","author":"Faivre","year":"2015","journal-title":"Cancer epidemiology, biomarkers & prevention"},{"key":"6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canep.2013.11.004","article-title":"Reproductive factors and breast cancer risk among BRCA1 or BRCA2 mutation carriers: results from ten studies","volume":"38","author":"Wang","year":"2014","journal-title":"Cancer epidemiology"},{"key":"7","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","article-title":"Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers","volume":"101","author":"Domchek","year":"2009","journal-title":"Journal of the National Cancer Institute"},{"key":"8","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1002\/cncr.21367","article-title":"Is BRCA1\/BRCA2-related breast carcinogenesis estrogen dependent?","volume":"104","author":"Pujol","year":"2005","journal-title":"Cancer"},{"key":"9","doi-asserted-by":"crossref","first-page":"7491","DOI":"10.1200\/JCO.2004.00.7138","article-title":"Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study","volume":"23","author":"Friedman","year":"2005","journal-title":"Journal of clinical oncology"},{"key":"10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/sj.onc.1204073","article-title":"Role of direct interaction in BRCA1 inhibition of estrogen receptor activity","volume":"20","author":"Rosen","year":"2001","journal-title":"Oncogene"},{"key":"11","doi-asserted-by":"crossref","first-page":"6557","DOI":"10.1158\/0008-5472.CAN-05-0486","article-title":"Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity","volume":"65","author":"Pestell","year":"2005","journal-title":"Cancer research"},{"key":"12","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1093\/jnci\/djm207","article-title":"Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer","volume":"99","author":"Couch","year":"2007","journal-title":"Journal of the National Cancer Institute"},{"key":"13","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1593\/neo.05256","article-title":"An estrogen receptor-alpha\/p300 complex activates the BRCA-1 promoter at an AP-1 site that binds Jun\/Fos transcription factors: repressive effects of p53 on BRCA-1 transcription","volume":"7","author":"Romagnolo","year":"2005","journal-title":"Neoplasia"},{"key":"14","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1210\/me.2004-0488","article-title":"The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells","volume":"20","author":"Rosen","year":"2006","journal-title":"Mol Endocrinol"},{"key":"15","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1210\/me.2008-0347","article-title":"Mechanism of BRCA1-mediated inhibition of progesterone receptor transcriptional activity","volume":"23","author":"Rosen","year":"2009","journal-title":"Mol Endocrinol"},{"key":"16","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/gcc.10321","article-title":"Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A","volume":"39","author":"Clarke","year":"2004","journal-title":"Genes, chromosomes & cancer"},{"key":"17","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1096\/fj.01-0498fje","article-title":"The estrogen-regulated protein, TFF1, stimulates migration of human breast cancer cells","volume":"16","author":"Westley","year":"2002","journal-title":"FASEB journal"},{"key":"18","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1126\/science.1130471","article-title":"Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist","volume":"314","author":"Lee","year":"2006","journal-title":"Science"},{"key":"19","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.286.18.2251","article-title":"Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial","volume":"286","author":"Fisher","year":"2001","journal-title":"JAMA"},{"key":"20","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/(SICI)1097-0215(19990621)84:3<263::AID-IJC11>3.0.CO;2-G","article-title":"Novel indications for BRCA1 screening using individual clinical and morphological features","volume":"84","author":"Sobol","year":"1999","journal-title":"International journal of cancer"},{"key":"21","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Tan-Chiu","year":"1998","journal-title":"Journal of the National Cancer Institute"},{"key":"22","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","article-title":"Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial","volume":"295","author":"James","year":"2006","journal-title":"JAMA : the journal of the American Medical Association"},{"key":"23","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1158\/1940-6207.CAPR-10-0076","article-title":"Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer","volume":"3","author":"James","year":"2010","journal-title":"Cancer Prev Res (Phila)"},{"key":"24","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1200\/JCO.2012.47.8313","article-title":"Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"31","author":"Nogues","year":"2013","journal-title":"Journal of clinical oncology"},{"key":"25","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","article-title":"Exemestane for breast-cancer prevention in postmenopausal women","volume":"364","author":"Garber","year":"2011","journal-title":"The New England journal of medicine"},{"key":"26","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2147\/IJWH.S50016","article-title":"Clinical utility of ulipristal acetate for the treatment of uterine fibroids: current evidence","volume":"7","author":"Koskas","year":"2015","journal-title":"International journal of women's health"},{"key":"27","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3109\/09513590.2014.950645","article-title":"The rationale for use of Ulipristal Acetate as first line in emergency contraception: biological and clinical evidence","volume":"30","author":"Glasier","year":"2014","journal-title":"Gynecological endocrinology"},{"key":"28","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1093\/humrep\/des221","article-title":"Ulipristal acetate does not impact human normal breast tissue","volume":"27","author":"Gompel","year":"2012","journal-title":"Hum Reprod"},{"key":"29","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.fertnstert.2010.09.059","article-title":"Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study","volume":"95","author":"Armstrong","year":"2011","journal-title":"Fertility and sterility"},{"key":"30","article-title":"Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids","author":"Bestel","year":"2014","journal-title":"Fertility and sterility"},{"key":"31","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1210\/mend.13.10.0356","article-title":"Effect of overexpression of progesterone receptor A on endogenous progestin-sensitive endpoints in breast cancer cells","volume":"13","author":"Clarke","year":"1999","journal-title":"Mol Endocrinol"},{"key":"32","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1128\/MCB.20.9.3102-3115.2000","article-title":"The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding","volume":"20","author":"McDonnell","year":"2000","journal-title":"Molecular and cellular biology"},{"key":"33","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12672-010-0009-7","article-title":"The role of sex steroid receptors on lipogenesis in breast and prostate carcinogenesis: a viewpoint","volume":"1","author":"Chalbos","year":"2010","journal-title":"Hormones & cancer"},{"key":"34","doi-asserted-by":"crossref","first-page":"5977","DOI":"10.1158\/0008-5472.CAN-05-4673","article-title":"Fatty acid synthase and cancer: new application of an old pathway","volume":"66","author":"Kuhajda","year":"2006","journal-title":"Cancer research"},{"key":"35","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1210\/jcem-70-5-1438","article-title":"Effects of progestins and menstrual cycle on fatty acid synthetase and progesterone receptor in human mammary glands","volume":"70","author":"Rochefort","year":"1990","journal-title":"The Journal of clinical endocrinology and metabolism"},{"key":"36","first-page":"43","article-title":"Regulation of fatty acid synthetase by progesterone in normal and tumoral human mammary glands","volume":"46","author":"Rochefort","year":"1990","journal-title":"Revista espanola de fisiologia"},{"key":"37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10549-011-1394-5","article-title":"Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells","volume":"131","author":"Gompel","year":"2012","journal-title":"Breast cancer research and treatment"},{"key":"38","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/gcc.20723","article-title":"Genomic alterations in histopathologically normal breast tissue from BRCA1 mutation carriers may be caused by BRCA1 haploinsufficiency","volume":"49","author":"Hedenfalk","year":"2010","journal-title":"Genes, chromosomes & cancer"},{"key":"39","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1038\/ncomms6496","article-title":"BRCA1 haploinsufficiency for replication stress suppression in primary cells","volume":"5","author":"Livingston","year":"2014","journal-title":"Nature communications"},{"key":"40","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/nm.2000","article-title":"Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers","volume":"15","author":"Thorne","year":"2009","journal-title":"Nature medicine"},{"key":"41","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nature14583","article-title":"Progesterone receptor modulates ERalpha action in breast cancer","volume":"523","author":"Pugh","year":"2015","journal-title":"Nature"},{"key":"42","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1002\/ijc.29304","article-title":"Progestin and antiprogestin responsiveness in breast cancer is driven by the PRA\/PRB ratio via AIB1 or SMRT recruitment to the CCND1 and MYC promoters","volume":"136","author":"Lanari","year":"2015","journal-title":"International journal of cancer"},{"key":"43","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/0895-4356(89)90161-3","article-title":"The independent associations of parity, age at first full term pregnancy, and duration of breastfeeding with the risk of breast cancer. Cancer and Steroid Hormone Study Group","volume":"42","author":"Ory","year":"1989","journal-title":"Journal of clinical epidemiology"},{"key":"44","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/bcr1029","article-title":"The protective role of pregnancy in breast cancer","volume":"7","author":"Russo","year":"2005","journal-title":"Breast cancer research"},{"key":"45","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1023\/A:1011253527605","article-title":"Grand multiparity and the risk of breast cancer: population-based study in Finland","volume":"12","author":"Kauppila","year":"2001","journal-title":"Cancer causes & control"},{"key":"46","article-title":"Tamoxifen and risk of contralateral breast cancer among women with inherited mutations in BRCA1 and BRCA2: a meta-analysis","author":"Wang","year":"2015","journal-title":"Breast Cancer"},{"key":"47","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/S1470-2045(13)70448-0","article-title":"The sex hormone system in carriers of BRCA1\/2 mutations: a case-control study","volume":"14","author":"Zaikin","year":"2013","journal-title":"The Lancet Oncology"},{"key":"48","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/sj.onc.1210674","article-title":"Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer","volume":"27","author":"Furth","year":"2008","journal-title":"Oncogene"},{"key":"49","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/GCO.0b013e3282f42237","article-title":"Promotion of BRCA1-associated triple-negative breast cancer by ovarian hormones","volume":"20","author":"Lee","year":"2008","journal-title":"Current opinion in obstetrics & gynecology"},{"key":"50","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/sj.bjc.6603042","article-title":"Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations","volume":"94","author":"Anderson","year":"2006","journal-title":"British journal of cancer"},{"key":"51","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1023\/A:1014820500738","article-title":"Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis","volume":"72","author":"Clarke","year":"2002","journal-title":"Breast cancer research and treatment"},{"key":"52","first-page":"77","article-title":"Progesterone receptor isoforms in normal and malignant breast","author":"Clarke","year":"2007","journal-title":"Ernst Schering Foundation symposium proceedings"},{"key":"53","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1741-7015-12-32","article-title":"Molecular determinants of context-dependent progesterone receptor action in breast cancer","volume":"12","author":"Lange","year":"2014","journal-title":"BMC medicine"},{"key":"54","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.mce.2014.05.011","article-title":"Epigenetic regulation of Progesterone Receptor isoforms: from classical models to the sexual brain","volume":"392","author":"Cerbon","year":"2014","journal-title":"Molecular and cellular endocrinology"},{"key":"55","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1210\/me.2011-1042","article-title":"p38 and p42\/44 MAPKs differentially regulate progesterone receptor A and B isoform stabilization","volume":"25","author":"Loosfelt","year":"2011","journal-title":"Mol Endocrinol"},{"key":"56","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10549-013-2722-8","article-title":"Loss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissue","volume":"142","author":"Gompel","year":"2013","journal-title":"Breast cancer research and treatment"},{"key":"57","doi-asserted-by":"crossref","first-page":"33422","DOI":"10.1074\/jbc.M201147200","article-title":"BRCA1-induced apoptosis involves inactivation of ERK1\/2 activities","volume":"277","author":"Cowan","year":"2002","journal-title":"The Journal of biological chemistry"},{"key":"58","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10549-013-2823-4","article-title":"Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers","volume":"143","author":"Senter","year":"2014","journal-title":"Breast cancer research and treatment"},{"key":"59","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1200\/JCO.2007.11.1179","article-title":"Oral contraceptives and breast cancer risk in the international BRCA1\/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group","volume":"25","author":"Berthet","year":"2007","journal-title":"Journal of clinical oncology"},{"key":"60","doi-asserted-by":"crossref","first-page":"7804","DOI":"10.1200\/JCO.2004.00.8151","article-title":"Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group","volume":"23","author":"Tomlinson","year":"2005","journal-title":"Journal of clinical oncology"},{"key":"61","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/jnci\/djn313","article-title":"Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers","volume":"100","author":"Friedman","year":"2008","journal-title":"Journal of the National Cancer Institute"},{"key":"62","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10549-016-3685-3","article-title":"Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study","volume":"155","author":"Singer","year":"2016","journal-title":"Breast cancer research and treatment"},{"key":"63","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.stem.2010.07.010","article-title":"BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells","volume":"7","author":"Smalley","year":"2010","journal-title":"Cell stem cell"},{"key":"64","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1177\/1933719114549850","article-title":"The clinical pharmacology and pharmacokinetics of ulipristal acetate for the treatment of uterine fibroids","volume":"22","author":"Gotteland","year":"2015","journal-title":"Reprod Sci"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.9638","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T11:34:48Z","timestamp":1596713688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.9638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,26]]},"references-count":64,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2016,7,19]]}},"alternative-id":["9638","27246982"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.9638","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,26]]}}}